Edurne San José-Enériz

Learn More
The development of Imatinib Mesylate (IM), the first specific inhibitor of BCR-ABL1, has had a major impact in patients with Chronic Myeloid Leukemia (CML), establishing IM as the standard therapy for CML. Despite the clinical success obtained with the use of IM, primary resistance to IM and molecular evidence of persistent disease has been observed in(More)
BACKGROUND The discrepancy between the functional improvements yielded experimentally by skeletal myoblasts (SM) transplanted in infarcted myocardium and the paucity of their long-term engraftment has raised the hypothesis of cell-mediated paracrine mechanisms. METHODS AND RESULTS We analyzed gene expression and growth factors released by undifferentiated(More)
Aberrant DNA methylation is one of the most frequent alterations in patients with Acute Lymphoblastic Leukemia (ALL). Using methylation bead arrays we analyzed the methylation status of 807 genes implicated in cancer in a group of ALL samples at diagnosis (n = 48). We found that 154 genes were methylated in more than 10% of ALL samples. Interestingly, the(More)
Leire Garate (lgarate@unav.es) Vanesa Martin (peperosa@teleline.es) Lucia Cordeu (lcordeu@unav.es) Amaia Vilas-Zornoza (avilaszo@alumni.unav.es) Paula Rodriguez-Otero (paurodriguez@unav.es) Maria Jose Calasanz (mjcal@unav.es) Felipe Prosper (fprosper@unav.es) Xabier Agirre (xaguirre@unav.es) This peer-reviewed article was published immediately upon(More)
  • 1